<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05036226</url>
  </required_header>
  <id_info>
    <org_study_id>103352</org_study_id>
    <nct_id>NCT05036226</nct_id>
  </id_info>
  <brief_title>COAST Therapy in Advanced Solid Tumors and Prostate Cancer</brief_title>
  <acronym>COAST</acronym>
  <official_title>Combination of Autophagy Selective Therapeutics (COAST) in Advanced Solid Tumors or Relapsed Prostate Cancer, A Phase I/II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5&#xD;
      study drugs used together for the treatment of solid tumor cancers. The drugs are&#xD;
      hydroxychloroquine, nelfinavir, metformin, dasatinib and sirolimus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2022</start_date>
  <completion_date type="Anticipated">October 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) - Phase I</measure>
    <time_frame>Minimum of 3 months after start of treatment on each dose level</time_frame>
    <description>Maximum dose achievable without dose limiting toxicities (DLT's)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of proportion of patients with disease control - Phase II</measure>
    <time_frame>Minimum of 16 weeks after start of treatment, per patient</time_frame>
    <description>Stable disease by RECIST or PCWG3 criteria after 16 weeks of treatment on study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life (QOL) score</measure>
    <time_frame>Minimum of 16 weeks of treatment on study</time_frame>
    <description>To document the change in QOL (via disease-specific FACT questionnaire, composite score) in patients treated with COAST) after two and four cycles of treatment</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Prostate Cancer Recurrent</condition>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 3a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 3b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Hydroxychloroquine, Metformin, Sirolimus</intervention_name>
    <description>Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily</description>
    <arm_group_label>Dose level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Hydroxychloroquine, Metformin, Sirolimus, Dasatanib</intervention_name>
    <description>Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Dasatinib 20mg daily</description>
    <arm_group_label>Dose level 2a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir</intervention_name>
    <description>Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 1250mg twice daily</description>
    <arm_group_label>Dose level 2b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib</intervention_name>
    <description>Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 1250mg twice daily Dasatanib 20mg daily</description>
    <arm_group_label>Dose level 3a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir</intervention_name>
    <description>Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 2500mg twice daily</description>
    <arm_group_label>Dose level 3b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib</intervention_name>
    <description>Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 2500mg twice daily Dasatanib 20mg daily</description>
    <arm_group_label>Dose level 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient must have advanced solid tumor cancer of any type (Phase I) or advanced&#xD;
             prostate cancer (Phase II).&#xD;
&#xD;
          2. Tissue diagnosis documented by pathology report, or clinic note attesting to same.&#xD;
&#xD;
          3. Measurable / evaluable tumor by RECIST, quantitative blood biomarker, or radionuclide&#xD;
             imaging&#xD;
&#xD;
          4. Voluntary, signed and dated, Institutional Review Board (IRB) approved consent form in&#xD;
             accordance with regulatory and institutional guidelines.&#xD;
&#xD;
          5. Documented progression of disease during treatment with one or more standard systemic&#xD;
             regimens. Single or multiple regimens of chemotherapy, hormone suppression therapy,&#xD;
             radiation therapy, surgery, immunotherapy, or adoptive cell therapy are allowed.&#xD;
&#xD;
          6. 18 years of age or older.&#xD;
&#xD;
          7. ECOG performance status of 0-2.&#xD;
&#xD;
          8. Bilirubin ≤ 1.5 times upper limit of normal (ULN) and AST / ALT ≤ 3 times ULN.&#xD;
             Subjects with Gilbert's syndrome may be included if the total bilirubin is &lt; 3 times&#xD;
             ULN and the direct bilirubin is within normal limits.&#xD;
&#xD;
          9. Serum creatinine ≤ 1.5 times ULN.&#xD;
&#xD;
         10. Absolute neutrophil count (ANC) ≥ 1,000 cells / mm3&#xD;
&#xD;
         11. Platelet count ≥ 75,000 cells / mm3&#xD;
&#xD;
         12. Hemoglobin ≥ 9 g/ dL.&#xD;
&#xD;
         13. Fasting glucose ≤ 160 mg/dL or non-fasting glucose ≤ 200 mg/dL.&#xD;
&#xD;
         14. Urinalysis with no clinically significant abnormalities.&#xD;
&#xD;
         15. Adequately controlled blood pressure as determined by the treating investigator.&#xD;
&#xD;
         16. Subjects with the potential to produce children must agree to effective contraceptive&#xD;
             method use during study participation.&#xD;
&#xD;
         17. Patients requiring narcotic analgesics must be on stable doses for at least 2 weeks&#xD;
             prior to study entry.&#xD;
&#xD;
         18. Patients being considered for a dose level containing nelfinavir mesylate must&#xD;
             discontinue any statin use within 48 hours of beginning study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. New York Heart Association Class III or IV, cardiac disease, myocardial infarction&#xD;
             within the past 6 months, unstable arrhythmia, or history of ischemia on ECG.&#xD;
&#xD;
          2. Underlying psychiatric disorder requiring hospitalization within the last two years.&#xD;
&#xD;
          3. Clinically significant neurological disorder (Parkinson's disease, dementia, multiple&#xD;
             sclerosis), as determined by the enrolling investigator.&#xD;
&#xD;
          4. Active, uncontrolled bacterial, viral, or fungal infection, requiring systemic&#xD;
             therapy.&#xD;
&#xD;
          5. Treatment with local or systemic radiation therapy, surgery, or investigational&#xD;
             therapy within 28 days prior to registration.&#xD;
&#xD;
          6. Unwillingness or inability to comply with procedures required in this protocol.&#xD;
&#xD;
          7. Serious nonmalignant disease that could compromise protocol objectives in the opinion&#xD;
             of the Investigator.&#xD;
&#xD;
          8. Patients who are receiving, coumadin, apixaban, argatroban or rivaroxaban.&#xD;
&#xD;
          9. Patients who are currently participating in any other clinical trial of an&#xD;
             investigational product.&#xD;
&#xD;
         10. Any other mental incapacitation or psychiatric illness that would preclude study&#xD;
             participation, as determined by the enrolling investigator.&#xD;
&#xD;
         11. Prisoners or patients who are compulsorily detained (involuntarily incarcerated) for&#xD;
             treatment of either a psychiatric or physical (e.g., infectious disease) illness must&#xD;
             not be enrolled into this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alan Brisendine</last_name>
    <phone>843-792-9007</phone>
    <email>brisend@musc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jasmin Brooks</last_name>
    <email>brooksjm@musc.edu</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Nelfinavir</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

